BAFNAPH NSI Week ended 07 Aug 2026

Weekly Investor Report

Bafna Pharmaceuticals Limited · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 285.0 INR
8.4% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 86.0% above the Trend Line and sits at 97.5% of its 52-week range. The latest completed week returned 8.4%, after a 39.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 55/100. Near-term considerations: price is close to its 52-week high.

Setup score 70 out of 100
Latest Close 285.0 INR 7 Aug 2026
1W Return 8.4% latest completed week
4W Return 39.3% short-term follow-through
12W Return 110.6% quarterly tape
Trend Breadth 61.5% 32 of 52 weeks active
Volume Ratio 9.6x vs 13-week average
What is working
  • The trend backdrop is active with a 8-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 42.33% based on similar historical setup states.
  • 6 reversal markers appear in the recent smart-money tape.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 8.4% Latest completed week; four-week move 39.3%. Indicator stack 62/81 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.33% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 55/100 12 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 86.0% above the Trend Line and sits at 97.5% of its 52-week range. The latest completed week returned 8.4%, after a 39.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 9.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7412-week average 0.59

12-week confirmation

Trend active8/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.74Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers66 reversal markers

No recent accumulation markers. 6 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 39.3% over four weeks, 110.6% over 12 weeks, and 233.8% over one year. The current trend has remained active for 8 consecutive weeks.

Performance by holding period

1W8.4%
4W39.3%
12W110.6%
26W145.7%
52W233.8%
Active trend streak8 weeks
Active weeks in one year32
Trend breadth61.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.65Latest activity-pressure read.
Pressure change22.5%Four-week change in activity pressure.
Leadership92.27Latest relative-leadership reading.
RS change72.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 91% Model confidence 85%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength21/100Blend of value, momentum, and quality. Underlying universe rank 80; rank 1 is best.
Value8/100Relative valuation strength. Underlying universe rank 93; rank 1 is best.
Quality32/100Profitability and accounting quality. Underlying universe rank 69; rank 1 is best.
Momentum100/100Medium-term price momentum. Underlying universe rank 1; rank 1 is best.
Growth72/100Revenue and earnings growth. Underlying universe rank 29; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework5/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
60.7x
Price divided by trailing earnings.
Price / sales
4.5x
Market value relative to trailing revenue.
EV / EBITDA
34.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-1.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
32.0%
Gross profit retained from each unit of revenue.
Operating margin
6.6%
Operating profit retained from revenue.
Free-cash-flow margin
-6.3%
Free cash flow generated from revenue.
Return on invested capital
5.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
3.3%
Latest one-year revenue growth.
EPS growth
167.3%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-3551.1%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment55/100

Weighted news tone is neutral across 12 relevant articles.

3 positive · 9 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-1.8%Distance below the 52-week high.
13-week volatility10.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+33.7%Week of 5 Jun.
Worst week-11.6%Week of 13 Mar.
Latest week+8.4%Week of 7 Aug.

Shape of recent returns

Strong gains11
Modest gains1
Flat weeks0
Modest losses8
Sharp losses6
Recent vol10.9%13-week weekly-return volatility.
Base vol11.8%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew13.2% / -5.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape65/100

Trend, activity pressure, participation, and risk combine to a 65/100 tape read.

 Indicator analysis70/100

Latest 12-week confirmation: trend 8/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.74; 6 reversal markers Next-Week ExpectancyNegative 42.33%

Next-week expectancy is negative with a 42.33% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors37/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 25; Small Cap Core rank 90 SVQF5/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 1496.0 of 1576 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment55/100

Weighted news tone is neutral across 12 relevant articles.

Bafna Pharmaceuticals Limited Revenue Breakdown – NSE:BAFNAPH Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 2026285.0 INR8.4%153.2 INR106.5 INR1.6592.27688.7KOn
31 Jul 2026262.9 INR10.4%148.3 INR105.3 INR1.5983.4614.7KOn
24 Jul 2026238.1 INR5.4%144.6 INR104.1 INR1.5874.6644.2KOn
17 Jul 2026225.9 INR10.4%142.1 INR103.2 INR1.4365.3511.1KOn
10 Jul 2026204.6 INR-5.5%139.6 INR102.3 INR1.3453.5826.4KOn
3 Jul 2026216.4 INR11.2%137.6 INR101.7 INR1.3365.0012.2KOn
26 Jun 2026194.7 INR21.5%135.2 INR100.9 INR1.2052.670On
19 Jun 2026160.2 INR-3.2%133.7 INR100.4 INR0.9828.1617.8KOn
12 Jun 2026165.4 INR-6.2%133.9 INR100.0 INR0.7936.4267.6KOff
5 Jun 2026176.3 INR33.7%134.4 INR99.74 INR0.5349.228.9KOff
29 May 2026131.9 INR-2.3%134.3 INR99.41 INR0.3712.7312.1KOff
22 May 2026135.0 INR-0.2%134.7 INR99.33 INR0.3615.728.2KOff
15 May 2026135.3 INR2.5%134.7 INR99.06 INR0.4017.5618.2KOff
8 May 2026132.0 INR-1.5%135.0 INR98.77 INR0.4013.358.2KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context